Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Current Deferred Revenue: 2011-2025

Historic Current Deferred Revenue for Arrowhead Pharmaceuticals (ARWR) over the last 13 years, with Sep 2025 value amounting to $2.4 million.

  • Arrowhead Pharmaceuticals' Current Deferred Revenue was N/A to $2.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.4 million, marking a year-over-year change of. This contributed to the annual value of $2.4 million for FY2025, which is N/A change from last year.
  • Arrowhead Pharmaceuticals' Current Deferred Revenue amounted to $2.4 million in Q3 2025, which was down 89.56% from $23.0 million recorded in Q2 2025.
  • In the past 5 years, Arrowhead Pharmaceuticals' Current Deferred Revenue registered a high of $150.9 million during Q2 2021, and its lowest value of $866,000 during Q3 2023.
  • Over the past 2 years, Arrowhead Pharmaceuticals' median Current Deferred Revenue value was $19.9 million (recorded in 2023), while the average stood at $19.6 million.
  • As far as peak fluctuations go, Arrowhead Pharmaceuticals' Current Deferred Revenue surged by 1,511.09% in 2021, and later tumbled by 99.33% in 2023.
  • Over the past 4 years, Arrowhead Pharmaceuticals' Current Deferred Revenue (Quarterly) stood at $108.7 million in 2021, then plummeted by 39.00% to $66.3 million in 2022, then slumped by 99.33% to $866,000 in 2023, then reached $2.4 million in 2025.
  • Its last three reported values are $2.4 million in Q3 2025, $23.0 million for Q2 2025, and $43.3 million during Q1 2025.